Patents by Inventor Maria-Clemencia Hernandez

Maria-Clemencia Hernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED BENZO[f][l ,2,4JTRIAZOL0[4,3-a][l ,4JDIAZEPINES AS GABA A GAMMA! POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20240002393
    Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Michael REUTLINGER, Valerie RUNTZ-SCHMITT, Jaclyn Ivy WAMSTEEKER CUSULIN, Nicolas ZORN
  • Isoxazolyl ether derivatives as GABA?5 PAM
    Patent number: 11840528
    Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 12, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
  • Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators
    Patent number: 11739095
    Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Luca Gobbi, Maria-Clemencia Hernandez, Frédéric Knoflach, Andreas Koblet, Eoin Cornelius O'Connor, Andres Miguel Olivares Morales, Michael Reutlinger, Valerie Runtz-Schmitt, Jaclyn Ivy Wamsteeker Cusulin, Nicolas Zorn
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    Publication number: 20230183225
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Application
    Filed: February 9, 2023
    Publication date: June 15, 2023
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230142171
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Roland HUMM, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT, Christian SCHNIDER
  • BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230141603
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds for treatment of CNS disorders.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Jaclyn WAMSTEEKER CUSULIN, Nicolas ZORN
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM
    Publication number: 20230136326
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: September 28, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT
  • TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20230135093
    Abstract: The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Emmanuel PINARD, Valerie RUNTZ-SCHMITT
  • NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230109111
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: September 23, 2022
    Publication date: April 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT
  • ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20220411415
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 16, 2021
    Publication date: December 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd BUETTELMANN, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20210309664
    Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 7, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Michael REUTLINGER, Valerie RUNTZ-SCHMITT, Jaclyn Ivy WAMSTEEKER CUSULIN, Nicolas ZORN
  • Isoxazolyl ether derivatives as GABA?5 PAM
    Patent number: 11091471
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20210094945
    Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    Publication number: 20210053959
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Application
    Filed: November 10, 2020
    Publication date: February 25, 2021
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas
  • ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20190300516
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd BUETTELMANN, Giuseppe CECERE, Bernhard FASCHING, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Emmanuel PINARD, Andrew THOMAS
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    Publication number: 20190270734
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Application
    Filed: March 27, 2019
    Publication date: September 5, 2019
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    Publication number: 20140343046
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 20, 2014
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas
  • Use of selective GABA A ?5 negative allosteric modulators for the treatment of central nervous system conditions
    Patent number: 8835425
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: September 16, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas
  • Triazole compounds I
    Patent number: 8742097
    Abstract: The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A ?5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 3, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria-Clemencia Hernandez, Matthew C. Lucas, Andrew Thomas
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    Publication number: 20120115839
    Abstract: The present invention relates to the pharmaceutical use of selective GABA A ?5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 10, 2012
    Inventors: Rodolfo Gasser, Maria-Clemencia Hernandez, Andrew Thomas